Just thought I would share this piece of information...
I went to a very interesting and informative BRCA carriers meeting in London on Monday. One of the presentations was about parp inhibitors and was given by Dr Rebecca Kristeleit, Senior Lecturer in Experimental Medicine and Consultant Medical Oncologist, UCL/UCLH. Included in the information presented about parp inhibitors was that 50% of high grade ovarian cancer could be BRCA-like (even if the patient tested negative for the BRCA 1 and 2 gene mutations)
Also at the meeting I met Ruth Payne from My Ovacome in person. It was a pleasure to finally meet you.
Best wishes to all